Modified protein reverses cirrhosis in lab rats

March 03, 2016

A protein modified to increase the amount of time it circulates in the bloodstream appears to reverse liver fibrosis and cirrhosis in rats, according to results of a study led by Johns Hopkins researchers.

The investigators say the findings, reported ahead of print in the March 3 early view edition of Hepatology, advance the search for a potential cure for the thousands of patients worldwide living with these incurable diseases. At present, there is little effective treatment and no cure other than liver transplantation, which carries its own risks and often fails.

"Our findings demonstrate that the damaging effects of liver cirrhosis in laboratory rats can be effectively treated, and perhaps even reversed, using a protein therapeutic that has been modified to enhance its activity through site-specific conjugation of a polymer that greatly enhances its residence time in the body," says senior author Justin Hanes, Ph.D., director of the Center for Nanomedicine at the Wilmer Eye Institute at Johns Hopkins. "This approach has tremendous potential to help people with this devastating condition and may also be helpful to the millions of patients with other diseases where fibrosis plays an important role."

Liver fibrosis and its more severe form, cirrhosis, are caused by scar tissue that forms in the liver that is usually induced by chronic alcohol abuse, infections and autoimmune diseases. The progressive stiffening of the liver, a hallmark of the disorders, occurs when a type of liver cell known as the hepatic stellate cell is "activated" and overproduces the stringy network of proteins called the extracellular matrix that binds cells together.

Being able to turn cirrhosis around, especially in its late stages, would be a great boon, says Seulki Lee, Ph.D., assistant professor in the Department of Radiology and Radiological Science at the Johns Hopkins University School of Medicine. "That's because liver fibrosis and cirrhosis can be asymptomatic for decades," Lee says. "Many patients only seek treatment when their disease becomes very advanced, at which point liver transplant is their only option."

Lee cautions, however, that his team's work is years from any possible application to patients.

Scientists have known for more than a decade that a protein called tumor necrosis factor-related apoptosis-inducing ligand -- TRAIL, for short -- can specifically kill activated hepatic stellate cells that overproduce the extracellular matrix, sparing healthy cells in the liver. However, Lee explains, TRAIL has thus far proven unsuccessful for clinical use because in animal studies, enzymes in the bloodstream quickly degrade it before it has time to work.

Seeking a way to extend TRAIL's half-life, or the time that it remains intact in the bloodstream, Lee and his colleagues coated TRAIL with polyethylene glycol (PEG), a synthetic polymer that's widely used as a preservative, lubricant and ingredient in skin creams, and is already being used to extend the bloodstream life of a handful of drugs that treat neutropenia, hemophilia and rheumatoid arthritis.

Lee says initial experiments showed that this "PEGylated" TRAIL had a half-life of between eight and nine hours in monkeys, compared to less than 30 minutes for the unmodified protein. When the scientists intravenously dosed rats that had liver fibrosis with the modified TRAIL for 10 days, the animals' activated hepatic stellate cells died off. By fighting these bad cells, signs of fibrosis began to diminish. Further investigation showed that multiple genes associated with fibrosis had reduced activity, and the proteins produced by these genes faded away.

Findings were similar in rats with advanced cirrhosis, Lee says. Additionally, when the researchers examined the rodents' liver tissue under a microscope, they found that animals treated with PEGylated TRAIL had fewer deposits of collagen and other extracellular matrix proteins, offering some evidence that the disease had actually been reversed.

Further experiments showed that PEGylated TRAIL selectively killed human-activated hepatic stellate cells growing in petri dishes while leaving normal liver cells unharmed, suggesting that findings in these animal models could apply to damaged human livers with limited toxicity concerns.

Lee says the research team hopes to develop PEGylated TRAIL for clinical trials in human patients in the next two years. He adds that some preliminary data suggest that the modified protein could also treat other fibrotic diseases as well, such as pancreatic or lung fibrosis, which also have no effective treatment.

"Eventually," Lee says, "we might be able to develop PEGylated TRAIL into a universal anti-fibrotic agent that can treat many different conditions."
Other Johns Hopkins researchers who participated in this study include Yumin Oh, Ogyi Park, Magdalena Swierczewska, James P. Hamilton, Jong-Sung Park, Tae Hyung Kim, Panagiotis Mastorakos, Clark Zhang and Martin G. Pomper. Other investigators are from the National Institute on Alcohol Abuse and Alcoholism, Sungkyunkwan University, Pohang University of Science and Technology, Seoul National University, and Korea Institute of Science and Technology.

This research was funded by the National Institute of Biomedical Imaging and Bioengineering under grant number EB013450, National Institute on Alcohol Abuse and Alcoholism under grant number AA000369, Department of Defense under grant number CA130460, and the National Research Foundation of Korea under grant numbers NRF-2013R1A1A2062043, NRF-2013R1A1A2064165 and NRF-2013K1A1A2A02050115.

Relevant disclosures: TRAILPEG for the study described in this release was provided by Theraly Pharmaceuticals Inc. Lee and Pomper are co-founders of the company, and Lee serves as its chief scientific officer. Both Lee and Pomper hold ownership equity in Theraly. This arrangement has been reviewed and approved by The Johns Hopkins University in accordance with its conflict of interest policies.

Johns Hopkins Medicine

Related Cirrhosis Articles from Brightsurf:

Researchers discover gene that could decrease likelihood of developing alcoholic cirrhosis
Researchers at Indiana University School of Medicine are learning more about how a person's genes play a role in the possibility they'll suffer from alcoholic cirrhosis with the discovery of a gene that could make the disease less likely.

When liver cirrhosis is deadly
A study by an international team of researchers headed by Professor Jonel Trebicka from the Frankfurt University Hospital and funded by the foundation EF Clif, has discovered which patients are particularly at risk for acute-on-chronic liver failure.

Blood tests can predict the risk of liver cirrhosis
Repeated measurements of the biomarker FIB-4 in the blood every few years can predict the risk of developing severe liver disease, according to a new study from Karolinska Institutet in Sweden published in the Journal of Hepatology.

Universal gut microbiome-derived signature predicts cirrhosis
UC San Diego School of Medicine researchers report that stool microbiomes of NAFLD patients are distinct enough to potentially be used to accurately predict which persons with NAFLD are at greatest risk for having cirrhosis.

Strength training benefits patients with cirrhosis
Three hours of weekly strength training combined with protein supplements leads to both bigger and stronger muscles in patients with cirrhosis.

Women are not more likely to die of cirrhosis than men, despite fewer liver transplants
Prior studies suggested women might have higher mortality of cirrhosis of the liver than men.

Movement toward a poop test for liver cirrhosis
In a study of people with nonalcoholic fatty liver disease and their twins and other close relatives, UC San Diego researchers were able to diagnose liver cirrhosis simply by analyzing a person's stool microbes.

Gum disease treatment may improve symptoms in cirrhosis patients
Routine oral care to treat gum disease (periodontitis) may play a role in reducing inflammation and toxins in the blood (endotoxemia) and improving cognitive function in people with liver cirrhosis.

Alcohol-related cirrhosis deaths skyrocket in young adults
Liver disease deaths jumped by 65 percent in the United States, from 1999-2016, disproportionately affecting adults ages 25-34.

Researchers find a promising new approach for treating liver cirrhosis
In a study in The American Journal of Pathology, investigators report that treatment with aleglitazar, a dual peroxisome proliferator-activated receptor-alpha/gamma (PPARα/γ) agonist, reduced inflammation, vasoconstriction, angiogenesis, mucosal disruption, and tumor necrosis factor (TNF)-α overproduction in cirrhotic rats with PH.

Read More: Cirrhosis News and Cirrhosis Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to